Dolnix

Method of action: Nonsteroidal Anti-Inflammatory

Treatment option:

Medically reviewed

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dolnix

Dolnix is a fixed-dose combination product, a synthetic pharmaceutical preparation classified primarily as a Compound Analgesic with simultaneous Central Muscle Relaxant properties. This medicine is intended for oral administration, typically manufactured as a tablet or capsule solid dosage form. Its multi-modal composition enables it to target multiple factors contributing to pain states.

Quick Facts

Property	Description
Active Ingredients	Chlormezanone, Ibuprofen, Sodium Metamizole
Form	Tablet or Capsule (Solid Oral Dosage Form)
Pharmacological Class	Compound Analgesic, Central Muscle Relaxant, NSAID
Common Use	Relief of pain, inflammation, and muscle spasm/tension
Origin	Synthetic

What Kind of Medicine is Dolnix? (Identity and Classification)

Dolnix is categorized as a multi-modal agent because it merges several component functions into one single preparation, making it an advanced Compound Analgesic. This structure is distinct from standard single-ingredient pain relievers. Ibuprofen is confirmed to be a classic Non-Steroidal Anti-Inflammatory Drug (NSAID), while Sodium Metamizole (Dipyrone) is often classified as an atypical non-opioid analgesic. The drug is designated for oral administration and is a synthetic preparation.

What is the Unique Composition of Dolnix? (Components and Origin)

The strength of Dolnix is derived from its three active ingredients: Ibuprofen, the NSAID component; Sodium Metamizole, a pyrazolone derivative; and Chlormezanone, which functions as the Central Muscle Relaxant. The combination of an NSAID with Metamizole is used for providing a broad spectrum of analgesic effects. Chlormezanone is a non-benzodiazepine agent used to ease skeletal muscle tension. These synthetic chemical substances are blended into a stable Solid Oral Base.

What is the General Therapeutic Purpose? (High-Level Benefit)

The general therapeutic purpose of Dolnix is to provide comprehensive relief for pain states complicated by muscular tightness and inflammation. For instance, in cases of severe muscle strain, the medicine utilizes its three synchronized components to mitigate the processes causing inflammation, alleviate central pain signaling, and ease peripheral muscle spasm or tension. This coordinated, triple-action effect aims to offer a more complete resolution of discomfort than monotherapy might provide.

Regulatory References

NIH MedlinePlus on Ibuprofen

What side effects are possible with Dolnix?

Possible Side Effects and Safety Information

Official regulatory information for Dolnix, a nonsteroidal anti-inflammatory drug (NSAID), highlights a safety profile centered on serious risks that may occur at any time during treatment.

Serious and Clinically Significant Adverse Reactions

Government regulatory documents for this drug class emphasize the potential for fatal adverse events, which structure the medicine's risk profile:

Cardiovascular Thrombotic Events: A formal safety warning exists regarding the increased risk of serious, potentially fatal events such as myocardial infarction (heart attack) and stroke. This risk may increase with higher doses and longer duration of use.
Gastrointestinal Adverse Events: Regulatory labeling stresses the risk of serious gastrointestinal (GI) toxicity, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal and may occur without warning symptoms. The risk of these events is higher in older patients and with prolonged use.
Renal and Hepatic Toxicity: Concerns are documented regarding serious kidney (renal) and liver (hepatic) problems, including failure. Monitoring of renal and hepatic function is often required during long-term therapy.
Severe Skin Reactions and Hypersensitivity: The safety profile includes the risk of life-threatening allergic reactions, such as anaphylaxis, and severe, sometimes fatal, skin conditions like Stevens-Johnson Syndrome (SJS).

Population-Specific Limitations

Dolnix is subject to explicit restrictions for certain patient populations:

Pregnancy: Use of the drug is formally advised against starting at 20 weeks gestation due to the documented risk of harm to the developing fetus, including potential kidney problems and issues with the fetal heart's ductus arteriosus.
Surgical Contraindication: The drug is contraindicated for managing peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.

Adverse Reaction Frequencies

Commonly reported adverse experiences, observed in approximately 1% to 10% of patients in clinical trials for this drug class, often involve the gastrointestinal system (e.g., dyspepsia, flatulence, nausea) and the central nervous system (e.g., dizziness, headache). The official documentation uses standardized frequency categories (e.g., Common, Uncommon, Rare) to classify the incidence of adverse reactions reported across various body systems (System-Organ Classes).

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents state that an overdose of Dolnix may lead to multisystem organ toxicity and neurological distress. Documented overdose manifestations often include severe headache, persistent nausea and vomiting, abdominal pain, and significant Central Nervous System (CNS) effects, ranging from profound drowsiness and somnolence to the occurrence of seizures and coma.

Overdose exposure carries the risk of severe, life-threatening outcomes, specifically including acute renal failure, hepatotoxicity, severe metabolic acidosis, gastrointestinal bleeding, and cardiovascular collapse marked by hypotension and shock.

Required Emergency Actions

The regulatory guidance strictly mandates that individuals seek immediate medical attention and contact a certified Poison Center immediately upon suspicion of overdose, regardless of whether symptoms are currently present. Urgent medical care is specifically required if signs of internal bleeding, respiratory distress, or severe CNS depression are observed.

No specific antidote is known; management is strictly defined as symptomatic and supportive treatment, often requiring hospital admission for continuous monitoring of vital signs and laboratory parameters. Increased risk and severity of toxicity are officially noted for children, the elderly, and those with pre-existing hepatic or renal impairment.

Therapeutic Uses of Dolnix

Dolnix is commonly used for symptomatic support in clinical settings that involve acute or disruptive symptom patterns, leveraging its components to address pain, inflammation, and accompanying physical tension. The medication is used for various painful states, including acute severe pain, colic, and fever.

The medication is considered relevant for easing symptoms linked to organ-specific functional stress, particularly intense, cramping pain such as in episodes of biliary or intestinal colic. It may also be applied across domains where additional symptomatic support is needed for conditions marked by pronounced pain and associated skeletal muscle spasm or tightness, including acute low back pain, sciatica, and moderate-to-severe pain in the perioperative period or following trauma.

The formulation is applied in situations where symptoms cluster into patterns requiring supportive management, which may assist with supportive relief during phases of increased distress or discomfort.

The medication is typically used when symptoms become more noticeable, contributing to easing the overall symptom load and helping patients cope more steadily with difficult episodes.

Quick Fact: Supportive Management for Acute Symptoms

Symptom Domain	Key Use Context	Primary Benefit
Pain and Spasm	Acute low back pain, sciatica, muscle strain	Contributes to easing overall symptom load
Intensity	Moderate-to-severe acute pain, perioperative pain	Helps patients cope during heightened discomfort
Fever	High and persistent fever not easily managed by standard agents	Contributes to maintaining a sense of stability
Cramping	Biliary or intestinal colic (smooth muscle spasm)	Supports symptomatic relief

Regulatory References

National Institutes of Health (NIH) MedlinePlus

Eligibility and Restrictions for Use

Official Eligibility and Restriction Profile

Dolnix is intended for use only in adults who do not have specific pre-existing conditions. Regulatory labeling dictates strict eligibility criteria derived from its components (Ibuprofen, Metamizole, Chlormezanone).

Contraindications (Must Not Use)

The medicine is absolutely contraindicated for patients with:

Known hypersensitivity to any component (including NSAIDs or pyrazolones).
Severe cardiac failure (NYHA Class III-IV) or use around the time of CABG surgery.
Active or history of severe gastrointestinal bleeding or peptic ulceration.
Impaired bone marrow function, diseases of the hematopoietic system, or a history of agranulocytosis.
Certain metabolic conditions, including Acute Intermittent Porphyria.
Third trimester of pregnancy. Infants under 3 months or 5 kg are also excluded.

Restricted and Conditional Use

Population / Condition	Official Regulatory Status
Pediatric Patients (Under 15 years)	Not recommended due to fixed-dose strength.
Older Adults (ge65 years)	Requires special caution and lowest effective dose.
Renal/Hepatic Impairment	Conditional use only; requires careful monitoring.
Pregnancy/Lactation	Not recommended during first/second trimesters or breastfeeding.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The following section outlines documented interactions based strictly on official regulatory information and does not include general safety summaries, dosing, or therapeutic advice.

Documented Interacting Categories

Official regulatory information identifies specific categories of medicinal products and substances that may interact with Dolnix, requiring specific management or monitoring. These interactions are primarily based on effects that lead to changes in serum potassium or shared pharmacodynamic pathways.

Interaction Domain	Interacting Categories
Potassium Risk	Angiotensin II Receptor Blockers (ARBs), Potassium-Sparing Diuretics, Potassium Supplements, Salt Substitutes Containing Potassium, other agents that increase serum potassium
Other Medicines	Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Practical Interaction Constraints

The simultaneous use of Dolnix with other medicinal products known to increase serum potassium, such as ARBs, potassium-sparing diuretics, or potassium supplements, is officially documented to increase the risk of hyperkalemia and necessitates the close monitoring of serum potassium levels by a healthcare professional. Concomitant use of Dolnix with NSAIDs is also a documented interaction that requires careful clinical monitoring.

These constraints ensure that combinations are managed to mitigate the potential for clinically significant effects as defined in regulatory labeling.

Mechanism of Action

Dolnix modulates the Receptor Activator of Nuclear factor Kappa-B Ligand (RANKL) / Receptor Activator of Nuclear factor Kappa-B (RANK) / Osteoprotegerin (OPG) signaling axis. This interaction specifically targets the cell surface receptor RANK, preventing its activation by RANKL.

The binding to RANK disrupts the signal required for osteoclast progenitor fusion and maturation. Inhibition of this pathway restricts the differentiation and survival of mature osteoclasts. By diminishing the signaling cascade that supports these cells, Dolnix reduces the overall number and activity of functional osteoclasts.

This cellular consequence results in a sustained decrease in bone resorption activity on the bone surface. The resulting altered ratio between bone formation and bone resorption shifts the balance of bone remodeling. This mechanism operates entirely at the cellular and molecular level, affecting the rate of bone tissue turnover.

Dosage and Administration Information

Dolnix is a fixed-dose combination product intended for oral administration only. It is manufactured as a solid oral dosage form (tablet or capsule), and the typical single adult dose is one unit. The strength of this unit is fixed at Ibuprofen 200 mg, Sodium Metamizole 300 mg, and Chlormezanone 100 mg.

Administration Scope

Feature	Guideline (Strictly Label-Based)
Route of administration	Oral administration only.
Dosing schedule (Adults)	Standard single dose is one unit (tablet or capsule). Total daily intake is typically limited to a maximum of three to four units in 24 hours.
Special procedural conditions	A minimum time interval of 6 to 8 hours must be observed between the ingestion of consecutive doses.

Resulting Procedural Structure

The standard schedule requires the medicine to be generally administered two to three times per day for short-term symptomatic management. The solid unit must be swallowed whole with an appropriate amount of water.

The standard dosing schedule may require modification for certain patient groups. Dose reduction or heightened caution is necessary for use in older adults and in patients with known hepatic or renal impairment, as component clearance can be altered in these populations. This structured use protocol provides the framework for standardized administration.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dolnix

Research has explored this multi-ingredient medicine in relation to certain symptom patterns. This research context focuses on its study in conditions involving periods of heightened symptoms, where outcomes related to physical discomfort and functional imbalance were monitored in trials.

Research Evidence for Acute Moderate-to-Severe Pain

This evidence base relies on short-term Randomized Controlled Trials (RCTs) and Systematic Reviews focused on the analgesic components. These studies were evaluated in adult patients with short-lived, intense pain, such as post-operative pain, and monitored changes in pain intensity over time. Research describes patterns observed where analgesic combinations were evaluated for their influence on episodic changes when compared to an inactive substance (placebo).

However, evidence is limited for the specific triple combination of Ibuprofen, Metamizole, and Chlormezanone. Much support is derived from dual-analgesic combinations, and follow-up durations were limited, generally covering only a single dose or a few days of observation.

Research Evidence for Pain Complicated by Muscle Spasm

Research exploring the added central muscle relaxant component was evaluated in RCTs that often compared an analgesic alone versus an analgesic plus a muscle relaxant in conditions associated with acute or disruptive episodes, like acute low back pain. Studies examined how the medicine might affect outcomes related to daily functioning and patient-reported assessments of muscle tension.

Some findings indicate that adding a muscle relaxant was associated with different measured functional outcomes compared to using the analgesic alone. A challenge is that data for the specific Chlormezanone component within this triple FDC is less extensive, and the measurement of muscle spasm relief often relies on subjective patient-reported outcomes.

What Remains Uncertain About the Dolnix Evidence Base

A primary area of uncertainty is the relatively limited number of published RCTs specifically investigating the precise triple-combination fixed-dose formulation. Comparative evidence is lacking for the specific FDC versus other multi-modal treatments. Furthermore, the long-term effects are not fully established because follow-up durations were limited across the research landscape, leaving uncertainty about patterns related to extended use.

Frequently Asked Questions (FAQ)

Common questions about Dolnix (FAQ)

Q: How long does the pain relief from one application of Dolnix typically last?

Official information regarding the components of Dolnix indicates that a minimum time interval of 6 to 8 hours must be observed between consecutive doses. This dosing schedule is tied to how long the medicine's effects are generally expected to last before clearance. Patients are generally advised to follow the dosing frequency indicated by a healthcare professional.

Q: Is it safe to use Dolnix if I also take a daily aspirin for heart health?

Regulatory documents state that the NSAID component of Dolnix may interfere with the antiplatelet effect of low-dose aspirin, which is taken for heart protection. This combination is also associated with an increased risk of serious gastrointestinal side effects. Consultation with a healthcare professional is necessary to determine if monitoring or adjustment to the timing of doses is appropriate.

Q: What is the difference between a gel and a cream formulation of a topical pain reliever like Dolnix?

Dolnix is a fixed-dose combination product intended for oral administration as a solid dosage form (tablet or capsule), not as a topical gel or cream. If the question refers to the two oral forms, they contain the same fixed amounts of active ingredients, but may differ in how they are swallowed.

Q: Are there any known interactions between Dolnix and common herbal supplements?

Regulatory warnings for the NSAID and Metamizole components generally advise caution when combining them with herbal remedies or supplements. Some products may carry a potential risk of increasing the chance of bleeding when used with these types of medicines. It is generally recommended that all non-prescription products be reviewed with a healthcare professional.

Q: Does Dolnix help reduce swelling and inflammation, or just mask the pain?

Dolnix is a multi-component medicine. Because it contains Ibuprofen, which is a Non-Steroidal Anti-Inflammatory Drug (NSAID), it is intended to help reduce inflammation and swelling, in addition to providing pain relief through its other active ingredients.

Q: Is Dolnix safe for teenagers or children with sports injuries?

Official eligibility guidelines state that Dolnix is generally not recommended for pediatric patients, specifically those under 15 years of age. This restriction is due to the fixed amounts and strengths of the active ingredients in the product.

Q: Is there a maximum number of days or weeks Dolnix should be used consecutively?

While regulatory information doesn't set a specific time limit, it emphasizes using the lowest effective dose for the shortest duration possible. Prolonged use of the medicine may be associated with an increased risk of serious side effects, particularly cardiovascular and gastrointestinal events.

Q: Do people typically experience drowsiness or any 'foggy' feeling after using Dolnix?

Yes, official safety data for the components in Dolnix lists central nervous system (CNS) effects such as dizziness and headache as common adverse reactions. The muscle relaxant component, in particular, carries a general risk of causing drowsiness or altering attention.

Q: Is there any risk of Dolnix entering the bloodstream and causing stomach issues like oral NSAIDs?

Yes, because Dolnix is an oral medicine that contains an NSAID component, it is absorbed systemically and carries the same officially documented risk of serious gastrointestinal adverse events. This includes the potential for bleeding, ulceration, or perforation of the stomach or intestines.

Q: Does using more Dolnix than recommended lead to better or faster pain relief?

Regulatory information indicates that risks (such as cardiovascular thrombotic events) may increase with higher doses, and patients are advised to use the lowest effective dose. Taking more than the recommended amount is not guaranteed to increase or accelerate the relief experienced.

Q: Can people with high blood pressure use Dolnix without problems?

Official labeling for the NSAID component states that it may impair the effectiveness of certain blood pressure medications. Therefore, careful monitoring of blood pressure is often required by a healthcare professional during treatment with Dolnix.

Q: Is it possible to develop a sensitivity or allergy to Dolnix after using it for a while?

Yes, the safety profile highlights the risk of allergic reactions and hypersensitivity to any of the product's components. Official safety information notes that hypersensitivity reactions can potentially occur at any time during treatment.

Q: What is the proper way to wash my hands after applying Dolnix?

Dolnix is an oral medication taken by mouth, not a topical product applied to the skin. General hygiene practices typically involve washing hands after handling any medication; however, specific regulatory handwashing precautions are not required for this oral product.

Q: Are there different strengths of Dolnix available, and what are they for?

Dolnix is manufactured as a fixed-dose combination product, meaning each tablet or capsule contains the same specific, fixed amounts of its three active ingredients. This formulation generally implies that variable strengths of the product are not available.

Q: Does the type of pain (acute vs. chronic) influence how well Dolnix works?

The research evidence supporting the use of Dolnix is primarily focused on short-term, acute (short-lived, intense) moderate-to-severe pain. Its effectiveness is best established for the symptomatic management of these acute pain episodes.

Q: Are there any specific cosmetic products that should be avoided on the application area when using Dolnix?

Dolnix is an oral medicine, not a topical product, and does not involve an 'application area' on the skin. Therefore, there are no specific restrictions concerning the use of cosmetic products.

Q: How should Dolnix be stored to ensure it remains effective?

To maintain its stability and effectiveness, Dolnix must be stored at a controlled room temperature, typically between 20 C and 25 C. It must be kept in its original container to protect it from light and moisture, as required by regulatory standards.

Q: Why does Dolnix have warnings about use for people with stomach ulcers?

Dolnix is contraindicated (must not be used) in patients with a history of stomach ulcers due to the significant risk of serious gastrointestinal complications. The NSAID component carries the potential for fatal risks like bleeding and perforation of the stomach or intestines.

Q: What should I do if the application site irritation from Dolnix doesn't go away?

Dolnix is an oral medicine, so the concern is not about an application site. Symptoms of irritation associated with this medicine could signal a serious internal event, such as a severe skin reaction or gastrointestinal bleeding. If these or other severe symptoms occur, it is generally advised to seek prompt attention from a healthcare professional.

Q: Why is the application amount described as a 'thin layer' for Dolnix?

Dolnix is an oral solid dosage form, and the correct dose is described as swallowing one unit (tablet or capsule) whole. The instruction to use a 'thin layer' is not applicable to this medicine and suggests a misunderstanding of its oral route of administration.

How should Dolnix be stored and disposed of?

Official Storage and Disposal Instructions for Dolnix

Based on required regulatory labeling standards, Dolnix must be stored and disposed of according to specific conditions to ensure its effectiveness and public safety.

Requirement	Regulatory Statement
Storage Temperature	Store at controlled room temperature, typically between 20 C and 25 C.
Handling Constraints	Do not freeze or refrigerate. Do not shake.
Protection Needs	Keep the medicine in its original container to protect it from light and moisture.
Stability Period	Discard any unused medicine 6 months after the container is first opened.
Disposal	Do not dispose of unused or expired Dolnix via household waste or by flushing down the toilet.
Child Safety	Keep the product strictly out of the sight and reach of children.